News & Updates
Search Research Content
Resource Finder at Kennedy Krieger Institute
A free resource that provides access to information and support for individuals and families living with developmental disabilities.
Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
|Title||Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.|
|Publication Type||Journal Article|
|Year of Publication||2012|
|Authors||Chau D, Becker D, Coombes M, Ioannidis G, Adachi J, Goeree R|
|Journal||Journal of medical economics|
|Volume||15 Suppl 1|
Denosumab is a novel biologic agent approved in Canada for treatment of post-menopausal osteoporosis (PMO) in women at high risk for fracture or who have failed or are intolerant to other osteoporosis therapies. This study estimated cost-effectiveness of denosumab vs usual care from the perspective of the Ontario public payer.
|Alternate Journal||J Med Econ|